1.0Innovations- und Gründerzentrum Biotechnologie IZBhttps://www.izb-online.de/en/Identification of new asthma targetsrich600338<blockquote class="wp-embedded-content" data-secret="BoflH2acWZ"><a href="https://www.izb-online.de/en/identifizierung-neuer-zielmolekuele-fuer-asthma/">Identification of new asthma targets</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.izb-online.de/en/identifizierung-neuer-zielmolekuele-fuer-asthma/embed/#?secret=BoflH2acWZ" width="600" height="338" title="“Identification of new asthma targets” — Innovations- und Gründerzentrum Biotechnologie IZB" data-secret="BoflH2acWZ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.izb-online.de/wp-includes/js/wp-embed.min.js
</script>
https://www.izb-online.de/wp-content/uploads/2020/04/Region_IZB-Weihenstaphan_Zielmoleküle-für-Asthma_Beitragsbild_Lungen_20192.jpg400255Pieris Pharmaceuticals, Inc., announced a research collaboration between the Company and two labs of the University of Pittsburgh on November 15. Pieris, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, will join forces with Professors Sally Wenzel, MD, and Anuradha Ray, PhD, to focus on comprehensive immune phenotyping of severe asthmatic patients.